Cizzle Biotechnology Holdings PLC Cash Flow Conversion Efficiency
Cizzle Biotechnology Holdings PLC cash flow conversion efficiency. Based on the latest financial reports, Cizzle Biotechnology Holdings PLC (CIZ) has a cash flow conversion efficiency ratio of 1.199x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-331.00K ≈ $-40.27 USD) by net assets (GBX-276.00K ≈ $-33.58 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cizzle Biotechnology Holdings PLC (2006–2024)
Cash flow conversion efficiency of Cizzle Biotechnology Holdings PLC from 2006 to 2024. This chart illustrates how Cizzle Biotechnology Holdings PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cizzle Biotechnology Holdings PLC share price for real-time trading data and today's change.
Cizzle Biotechnology Holdings PLC Cash Flow Conversion Ratio Explained
Cizzle Biotechnology Holdings PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cizzle Biotechnology Holdings PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cizzle Biotechnology Holdings PLC ranked by their cash flow conversion efficiency. Also see CIZ stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanoco Group plc
LSE:NANO
|
-0.051x |
|
Image Scan Holdings Plc
LSE:IGE
|
-0.246x |
|
GOLCAP RESOURCES CORP
F:2SO0
|
-0.030x |
|
Trakm8 Holdings PLC
LSE:TRAK
|
-0.013x |
|
MyHealthChecked Plc
LSE:MHC
|
-0.067x |
|
Selina Hospitality PLC
NASDAQ:SLNAF
|
-0.016x |
|
Northann Corp.
NYSE MKT:NCLX
|
-0.076x |
|
Sporttotal AG
F:WIG1
|
0.078x |
Annual Cash Flow Conversion Efficiency for Cizzle Biotechnology Holdings PLC (2006–2024)
The table below shows the annual cash flow conversion efficiency of Cizzle Biotechnology Holdings PLC from 2006 to 2024. Review Cizzle Biotechnology Holdings PLC (CIZ) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX82.00K ≈ $9.98 |
GBX-358.00K ≈ $-43.56 |
-4.366x | -929.63% |
| 2023-12-31 | GBX1.51 Million ≈ $183.36 |
GBX-639.00K ≈ $-77.75 |
-0.424x | -28.37% |
| 2022-12-31 | GBX2.64 Million ≈ $321.21 |
GBX-872.00K ≈ $-106.10 |
-0.330x | +69.33% |
| 2021-12-31 | GBX937.00K ≈ $114.01 |
GBX-1.01 Million ≈ $-122.77 |
-1.077x | +88.28% |
| 2020-12-31 | GBX32.00K ≈ $3.89 |
GBX-294.00K ≈ $-35.77 |
-9.188x | -761.46% |
| 2019-12-31 | GBX6.63K ≈ $0.81 |
GBX-7.07K ≈ $-0.86 |
-1.067x | -148.86% |
| 2018-12-31 | GBX-235.00K ≈ $-28.59 |
GBX-513.00K ≈ $-62.42 |
2.183x | +951.36% |
| 2017-12-31 | GBX741.00K ≈ $90.16 |
GBX-190.00K ≈ $-23.12 |
-0.256x | -401.49% |
| 2016-12-31 | GBX2.19 Million ≈ $266.09 |
GBX186.00K ≈ $22.63 |
0.085x | +135.88% |
| 2015-12-31 | GBX2.40 Million ≈ $292.62 |
GBX-570.00K ≈ $-69.35 |
-0.237x | -127.41% |
| 2014-12-31 | GBX5.05 Million ≈ $614.07 |
GBX-526.00K ≈ $-64.00 |
-0.104x | +34.38% |
| 2013-12-31 | GBX4.27 Million ≈ $519.41 |
GBX-678.00K ≈ $-82.49 |
-0.159x | -424.98% |
| 2012-12-31 | GBX4.79 Million ≈ $583.17 |
GBX-145.00K ≈ $-17.64 |
-0.030x | +91.82% |
| 2011-12-31 | GBX4.08 Million ≈ $496.90 |
GBX-1.51 Million ≈ $-183.72 |
-0.370x | -329.38% |
| 2010-12-31 | GBX3.54 Million ≈ $430.96 |
GBX-305.00K ≈ $-37.11 |
-0.086x | +70.09% |
| 2009-12-31 | GBX521.00K ≈ $63.39 |
GBX-150.00K ≈ $-18.25 |
-0.288x | +69.03% |
| 2008-12-31 | GBX1.67 Million ≈ $202.70 |
GBX-1.55 Million ≈ $-188.47 |
-0.930x | -6.47% |
| 2007-12-31 | GBX2.40 Million ≈ $291.89 |
GBX-2.10 Million ≈ $-254.90 |
-0.873x | -104.62% |
| 2006-12-31 | GBX-58.00K ≈ $-7.06 |
GBX-1.10 Million ≈ $-133.47 |
18.914x | -- |
About Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings … Read more